This webinar will introduce novel chemically modified oligonucleotide tools that have the potential to treat multifactorial conditions (including cancer and drug resistance challenges) while overcoming the limits of oligonucleotide therapies.
Among the various oligonucleotide tools presented, particular emphasis will be placed on innovative multi-target nanostructures that have been designed to administer several oligonucleotide therapeutics in a single dose, each of which is active against a distinct therapeutic target.
You will also have the opportunity to learn about their functionalization with accessory molecules, such as fluorophores and targeting peptides, to monitor their distribution in tumors.
Key topics
- Novel chemical modifications to enhance oligonucleotide biostability.
- Peptide conjugation for targeted delivery of therapeutic oligonucleotides to tumors.
- Multi-target strategies for delivering multiple oligonucleotide therapies in a single dose.
What to expect
This will be a presentation of some new chemical modification approaches that can be used to:
- Improve oligonucleotide drug resistance to 3'-exonuclease degradation.
- Develop robust siRNA prodrugs that act as Dicer substrates.
- Combine numerous oligonucleotide medicines into a single structure for selective cleavage by certain intracellular triggers, such as endogenous enzymes.
About the speakers
Montserrat Terrazas obtained her Ph.D. from the University of Barcelona (UB) in 2006. She completed postdoctoral studies at KU Leuven, Stanford University, and IQAC-CSIC. She also worked as a Miguel Servet Fellow at IRB-Barcelona from 2014 to 2020. In 2021, she was named an Associate Professor at UB.
Martial Piotto received his Ph.D. in NMR spectroscopy from the University of Purdue, US (Pr. D. Gorenstein). He later joined Bruker France as head of NMR application, where he worked on a variety of NMR spectroscopy projects, including the development of new pulse sequences and HRMAS technology.
Over time, he became interested in NMR applications in the pharmaceutical and medical fields. His current study focuses on the characterization of biologics (mAbs, vaccines, and therapeutic oligonucleotides) using NMR and multivariate statistical methods.